Stock Events

Applied Dna Sciences 

$0.44
57
+$0.02+5.21% Friday 19:59

Statistics

Day High
0.45
Day Low
0.39
52W High
37.2
52W Low
0.33
Volume
1,378,334
Avg. Volume
1,523,281
Mkt Cap
3.97M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

10MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-4.5
-3
-1.51
-0.01
Expected EPS
-4.5
Actual EPS
-2.71

People Also Follow

This list is based on the watchlists of people on Stock Events who follow APDN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap16.63B
Illumina provides sequencing and array-based solutions for genetic analysis, competing in the biotechnology and diagnostics sectors similar to APDN.
Qiagen NV
QGEN
Mkt Cap9.38B
Qiagen offers sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, directly competing with APDN's DNA-based technologies.
Pacific Biosciences of California
PACB
Mkt Cap373.13M
Pacific Biosciences offers sequencing systems that compete with APDN in the genomics and DNA sequencing markets.
Bio-Rad Laboratories
BIO
Mkt Cap7.84B
Bio-Rad Laboratories provides a range of products and systems used to separate complex chemical and biological materials, competing in the life sciences research and clinical diagnostics markets.
Thermo Fisher Scientific
TMO
Mkt Cap211.09B
Thermo Fisher Scientific offers a broad range of services and products, including analytical instruments and reagents, which compete with APDN's offerings in the life sciences sector.
Guardant Health
GH
Mkt Cap3.53B
Guardant Health focuses on liquid biopsies and cancer diagnostics, competing with APDN in the molecular diagnostics market.
Fulgent Genetics
FLGT
Mkt Cap587.11M
Fulgent Genetics provides comprehensive genetic testing solutions, competing with APDN in the DNA sequencing and genetic analysis market.
Adaptive Biotechnologies
ADPT
Mkt Cap533.47M
Adaptive Biotechnologies offers immune-driven medicine solutions, competing with APDN in the biotech sector focusing on genetic and molecular diagnostics.
CRISPR Therapeutics
CRSP
Mkt Cap4.59B
CRISPR Therapeutics is involved in gene editing, a field that overlaps with the genetic technologies and services provided by APDN.

Analyst Ratings

1.5$Average Price Target
The highest estimate is $1.5.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Information Technology Services
Pharmaceuticals: Major
Technology Services
Cyclic Crude, Intermediate, and Gum and Wood Chemical Manufacturing
Miscellaneous Commercial Services
Commercial Services
Manufacturing
Health Technology
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
Show more...
CEO
James Hayward
Employees
52
Country
US
ISIN
US03815U3005
WKN
000A2PUTA

Listings